FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of July 2025
Commission File Number: 001-36187
EVOGENE LTD.
(Translation of Registrant’s Name into English)
13 Gad Feinstein Street, Park Rehovot, Rehovot
7638517, Israel
(Address of principal executive offices)
On July 8, 2025, and following its report from April 21, 2025, Evogene Ltd., or Evogene, announced that its
subsidiary, Lavie Bio Ltd., or Lavie Bio, completed the previously announced transaction with Dead Sea Works Ltd. (an affiliate of ICL Group Ltd.), or ICL, pursuant to which ICL acquired most of the activity of Lavie Bio.
A copy of the press release whereby Evogene and Lavie Bio made the foregoing announcement is furnished as Exhibit
99.1 hereto.
The content of this Form 6-K (excluding Exhibit 99.1) is incorporated by reference into the registration statements
on Form F-3 (File Nos. 333-277565 and 333-253300 ), and on Form S-8 (File Nos. 333-193788, 333-201443, 333-203856, 333-286197 and 333-259215) of the Company, filed with the Securities and Exchange Commission, to be a part thereof from the date on
which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report
to be signed on its behalf by the undersigned, thereunto duly authorized.